Literature DB >> 27855355

Seizure control and cognitive improvement via immunotherapy in late onset epilepsy patients with paraneoplastic versus GAD65 autoantibody-associated limbic encephalitis.

N Hansen1, G Widman2, J-A Witt2, J Wagner3, A J Becker4, C E Elger2, C Helmstaedter2.   

Abstract

OBJECTIVE: To determine the efficacy of immunotherapy in limbic encephalitis (LE) associated epilepsies with autoantibodies against intracellular antigens in the forms of paraneoplastic autoantibodies versus glutamic acid decarboxylase 65 (GAD)-autoantibodies.
METHODS: Eleven paraneoplastic-antibodies+ and eleven age- and gender-matched GAD-antibodies+ patients with LE were compared regarding EEG, seizure frequency, MRI volumetry of the brain, and cognition. All patients received immunotherapy with corticosteroids add-on to antiepileptic therapy. A few patients underwent additional interventions like immunoglobulins or immunoadsorption.
RESULTS: Immunotherapy led to a significantly greater proportion of seizure-free patients in the paraneoplastic antibodies+(55%) as compared to GAD-antibodies+(18%) patients (p<0.05). Impaired cognition was evident initially (total cognitive performance score based on attentional-executive function, figural/verbal memory and word fluency) in 100% of the paraneoplastic-antibodies+ and 73% of the GAD-antibodies+ group. After therapy, cognition improved significantly in the paraneoplastic-antibodies+, but not in the GAD-antibodies+ patients (p<0.05). Cognitive change did not correlate with the change in the number of antiepileptic drugs over time. MRI showed larger and unchanged volumes of the amygdala, presubiculum and subiculum in GAD-antibodies+as compared to paraneoplastic-antibodies+patients (p<0.05) over time.
CONCLUSIONS: Our data provide evidence of a beneficial effect of immunotherapy added to antiepileptic drugs on seizure frequency and cognition only in the paraneoplastic-antibodies+ subgroup of LE presenting autoantibodies against intracellular antigens.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epilepsy; GAD65 autoantibodies; Immunotherapy; Limbic encephalitis; Paraneoplastic autoantibodies

Mesh:

Substances:

Year:  2016        PMID: 27855355     DOI: 10.1016/j.yebeh.2016.10.016

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  19 in total

Review 1.  Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions.

Authors:  Michelle A Erickson; William A Banks
Journal:  Pharmacol Rev       Date:  2018-04       Impact factor: 25.468

Review 2.  Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis.

Authors:  Marianna Spatola; Josep Dalmau
Journal:  Curr Opin Neurol       Date:  2017-06       Impact factor: 5.710

3.  A Survival Case of Super-refractory Status Epilepticus due to Glutamic Acid Decarboxylase Antibodies-associated Limbic Encephalitis.

Authors:  Baoqiong Liu; Yan Zhou; Lingbin Meng; Holly Skinner
Journal:  Cureus       Date:  2018-08-10

4.  Neuropsychological Performance in Autoimmune Limbic Encephalitis: Evidence from an Immunotherapy-Naïve Cohort.

Authors:  Christoph Mueller; Lisa Langenbruch; Johanna M H Rau; Tobias Brix; Christine Strippel; Andre Dik; Kristin S Golombeck; Constanze Mönig; Andreas Johnen; Saskia Räuber; Heinz Wiendl; Sven G Meuth; Jens Bölte; Stjepana Kovac; Nico Melzer
Journal:  Arch Clin Neuropsychol       Date:  2022-05-16       Impact factor: 3.448

5.  Anti-kindling effect of Ginkgo biloba leaf extract and L-carnitine in the pentylenetetrazol model of epilepsy.

Authors:  Amina E Essawy; Soad Ahmed El-Sayed; Ehab Tousson; Horeya S Abd El-Gawad; Reem Hasaballah Alhasani; Heba-Tallah Abd Elrahim Abd Elkader
Journal:  Environ Sci Pollut Res Int       Date:  2022-02-22       Impact factor: 5.190

Review 6.  What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review.

Authors:  Sverre Georg Sæther; Morten Schou; Daniel Kondziella
Journal:  BMC Psychiatry       Date:  2017-05-03       Impact factor: 3.630

Review 7.  Neurological Syndromes Associated with Anti-GAD Antibodies.

Authors:  Maëlle Dade; Giulia Berzero; Cristina Izquierdo; Marine Giry; Marion Benazra; Jean-Yves Delattre; Dimitri Psimaras; Agusti Alentorn
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

8.  Clinical Management of Epilepsy With Glutamic Acid Decarboxylase Antibody Positivity: The Interplay Between Immunotherapy and Anti-epileptic Drugs.

Authors:  Kari-Matti Mäkelä; Aki Hietaharju; Antti Brander; Jukka Peltola
Journal:  Front Neurol       Date:  2018-07-13       Impact factor: 4.003

Review 9.  Immunotherapy in Autoantibody-Associated Psychiatric Syndromes in Adults.

Authors:  Niels Hansen; Charles Timäus
Journal:  Front Psychiatry       Date:  2021-01-28       Impact factor: 4.157

10.  Intravenous methylprednisolone or immunoglobulin for anti-glutamic acid decarboxylase 65 antibody autoimmune encephalitis: which is better?

Authors:  Tao-Ran Li; Yu-Di Zhang; Qun Wang; Xiao-Qiu Shao; Zhi-Mei Li; Rui-Juan Lv
Journal:  BMC Neurosci       Date:  2020-03-30       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.